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Abstract
A number of preclinical studies have demonstrated an-
ticancer effects for curcumin in various types of tumors, 
including pancreatic cancer. Curcumin has anticancer ef-
fects both alone and in combination with other antican-
cer drugs (e.g. , gemcitabine, 5-fluorouracil, and oxali-
platin), and it has been shown to modulate a variety of 
molecular targets in preclinical models, with more than 
30 molecular targets identified to date. Of these various 
molecules, NF-kB is thought to be one of the primary 
targets of curcumin activity. Based on these promising 
preclinical results, several research groups, including 
our own, have progressed to testing the anticancer ef-
fects of curcumin in clinical trials; however, the poor 
bioavailability of this agent has been the major chal-
lenge for its clinical application. Despite the ingestion of 
gram-level doses of curcumin, plasma curcumin levels 
remain at low (ng/mL) levels in patients, which is insuf-
ficient to yield the anticancer benefits of curcumin. This 
problem has been solved by the development of highly 
bioavailable forms of curcumin (THERACURMIN®), and 
higher plasma curcumin levels can now be achieved 
without increased toxicity in patients with pancreatic 
cancer. In this article, we review possible therapeutic 
applications of curcumin in patients with pancreatic 
cancer.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: A growing body of evidence supports the idea 
that curcumin is a promising anticancer drug. Curcumin 
has anticancer effects, both alone and in combination 
with other anticancer drugs, through the modulation 
of a variety of molecular targets in preclinical models. 
However, the poor bioavailability of curcumin has been 
the major challenge to its clinical application. This prob-
lem has been overcome by the development of highly 
bioavailable forms of curcumin (THERACURMIN®), and 
higher plasma curcumin levels can now be achieved 
without increased toxicity. Further clinical trials will be 
necessary to test the therapeutic applications of this 
promising agent in patients with pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is one of  the most lethal malignancies 
worldwide[1], and the majority of  patients are diagnosed 
too late for curative resection. Even in patients who have 
undergone curative resection, the disease relapse rate 
within 2 years is greater than 80%[2]. Systemic gemcitabi-
ne-based chemotherapy has been a standard therapy for 
patients with advanced pancreatic cancer since 1997, 
when a randomized phase Ⅲ study demonstrated that 
gemcitabine monotherapy significantly improved cancer-
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related symptoms compared with 5-fluorouracil[3]. Over 
the past decade, many efforts have been made to im-
prove the overall survival of  patients with this disease by 
combining gemcitabine with a second cytotoxic agent. 
However, most of  these gemcitabine combination thera-
pies have failed to show significant survival advantages 
over gemcitabine monotherapy[4-11]. Therefore, novel ap-
proaches - other than simply adding additional cytotoxic 
agents to gemcitabine - are warranted. In addition, it is 
important to consider the balance between efficacy and 
quality of  life when choosing a palliative chemotherapy, 
as patients with pancreatic cancer often suffer from can-
cer-related symptoms, such as fatigue, appetite loss, and 
pain.
Curcumin is a natural polyphenol compound derived 
from turmeric (Curcuma longa). Constituting 1%-5% of  
turmeric preparations, curcumin has a molecular weight 
of  368.37 and the molecular formula C21H20O6 (Figure 
1). Curcumin has long been used as a food (e.g., in the 
popular Indian curry), a coloring agent and in traditional 
medicine[12,13]. A number of  preclinical studies have dem-
onstrated that curcumin has anticancer effects against a 
variety of  tumors, including pancreatic cancer, both in vi-
tro and in vivo[14-32]. These promising results have attracted 
the interest of  many researchers hoping to develop this 
agent as a chemopreventive as well as a chemotherapeutic 
drug[33,34]. In contrast with conventional cytotoxic drugs 
- which often have side effects such as nausea, vomiting 
or fatigue - curcumin has minimal toxicity. This is a great 
advantage when treating patients with pancreatic cancer, 
who generally show poor tolerance to intensive therapy 
due to their poor clinical conditions. Safety is another 
advantage of  this agent. The safety of  curcumin has 
been approved by the Food and Drug Administration 
and World Health Organization; In addition, its safety is 
strongly supported by the fact that this agent has been 
used in traditional Hindu and Chinese medicine for thou-
sands of  years.
In this article, we review possible therapeutic appli-
cations of  curcumin for the treatment of  patients with 
pancreatic cancer.
ANTICANCER EFFECTS OF CURCUMIN 
AGAINST PANCREATIC CANCER IN 
VITRO AND IN VIVO
A PubMed search using the key words ‘‘curcumin’’ and 
‘‘cancer’’ reveals that over 2000 articles have been pub-
lished on this topic since 1983, with that number increas-
ing rapidly year after year. Numerous preclinical stud-
ies have demonstrated anticancer effects for curcumin 
against not only pancreatic cancer[14,17,22,24,26-28,32,35] but also 
a variety of  other malignancies, including breast[21], co-
lon[23,29], gastric[30], head and neck[25], hepatic[15], ovarian[20], 
lung[31]and prostate cancers[19], as well as lymphoma and 
leukemia[16,18].
Li et al[14] were the first to report the anticancer effects 
of  curcumin against pancreatic cancer cells. They dem-
onstrated that curcumin can suppress tumor growth in 
pancreatic cancer cell lines in a time- and dose-dependent 
manner by inhibiting nuclear transcription factor-kappa 
B (NF-kB). The efficacy of  curcumin has also been dem-
onstrated using an orthotopic mouse model of  pancre-
atic cancer[36]. Although treatment with either curcumin (1 
g/kg orally) or gemcitabine (25 mg/kg via intraperitoneal 
injection) had modest antitumor effects, the combination 
of  curcumin and gemcitabine suppressed tumor growth 
more effectively than either agent alone. In addition to 
gemcitabine, curcumin has also been shown to potentiate 
the effects of  other cytotoxic agents, including cisplatin, 
oxaliplatin, and 5-fluorouracil, in preclinical models[25,29,37].
Curcumin can modulate the activity of  a variety of  
molecules that play important roles in cancer progression, 
with more than 30 molecular targets identified to date[38]. 
Of  these molecules, NF-kB appears to be one of  the 
primary targets of  curcumin[14,27,36]. Interestingly, recent 
studies have demonstrated that changes in microRNA 
(miRNA) expression levels following treatment with cur-
cumin or a curcumin analog are involved in the anticancer 
effects of  these agents[28,39]. For example, curcumin can 
upregulate the expression of  miR-200[28], which plays im-
portant roles in regulating the epithelial-to-mesenchymal 
transition (EMT) and cancer progression[40]. Conversely, 
curcumin can downregulate the expression of  miR-21[28], 
which is overexpressed in a variety of  tumors, including 
pancreatic cancer, and is considered to be an oncogenic 
miRNA[41]. Representative preclinical studies of  the anti-
cancer effects of  curcumin against pancreatic cancer are 
summarized in Table 1.
Based on these promising preclinical results, several 
researcher groups, including our own, have progressed to 
testing the anticancer effects of  curcumin in clinical trials.
CLINICAL TRIALS INVOLVING CURCUMIN 
IN PATIENTS WITH PANCREATIC 
CANCER
Despite numerous published preclinical studies, rela-
tively few clinical trials have been reported so far. Several 
phase Ⅰ and pharmacokinetic studies have been conduct-
ed using curcumin, and they found no dose-limiting tox-
icity (DLT) up to at least 12 g/d when administered orally 
to both healthy volunteers[42,43] and cancer patients[44-46]. 
The minor toxicities of  Grade 1-2 diarrhea and nausea 
have been reported, although these were likely due to the 
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Figure 1  Chemical structure of curcumin.
ingestion of  large volumes of  curcumin at one time. Due 
to poor bioavailability, curcumin doses greater than 8 
g/d do not lead to further increases in plasma curcumin 
levels; therefore, daily oral doses of  8 g or less have been 
most commonly used in clinical trials.
Dhillon et al[47] were the first to report a phase Ⅱ 
clinical trial of  the effects of  curcumin against pancreatic 
cancer. Twenty-five patients, including 3 chemo-naive pa-
tients, were enrolled in this study. Of  the 22 patients that 
could be evaluated for responses, one patient showed 
a stable disease course for over 18 mo and another pa-
tient showed a partial response in a liver metastasis (73% 
decrease in size), although this effects lasted for only 1 
month. Furthermore, curcumin treatment was found to 
be safe in patients with pancreatic cancer, and no toxicity 
was associated with curcumin intake.
Our group conducted a phase Ⅰ/Ⅱ clinical trial of  
curcumin in patients with pancreatic cancer who had 
become resistant to gemcitabine-based chemotherapy[48]. 
In contrast with the study by Dhillon et al[47], which tested 
the safety and efficacy of  curcumin monotherapy, our 
study evaluated the efficacy of  combined gemcitabine-
based chemotherapy and curcumin treatment, which 
we tested based on the preclinical results showing that 
curcumin could potentiate the anticancer effects of  gem-
citabine[36]. As no previous studies had demonstrated the 
safety and feasibility of  this drug combination in cancer 
patients, we began with a phase Ⅰ study involving an 8-g 
daily oral dose of  curcumin in combination with gem-
citabine-based chemotherapy. The first 3 patients that 
could be assessed completed their first treatment cycle 
without a predefined DLT. Therefore, we selected this 
dose for the following phase Ⅱ study. In total, 21 patients 
who showed disease progression during previous gem-
citabine-based chemotherapy were enrolled in the study. 
The addition of  an 8-g daily oral curcumin dose did not 
increase the risk of  clinically relevant toxicity, and the 
toxicity profile of  the combined drugs was comparable 
with that observed in pancreatic cancer patients treated 
with gemcitabine-based chemotherapy alone. Cumulative 
toxicity from curcumin was not observed, and 4 patients 
were able to continue this intake regimen for over 6 mo, 
indicating that this agent is safe for long-term use. Even 
though the preliminary results were from a small sample, 
the observed median survival time (MST) of  5.4 (95%CI 
3.6-7.4) mo and a 1-year survival rate of  19% (95%CI 
4.4%-41.4%) are promising results, particularly consider-
ing the poor prognosis of  patients with pancreatic cancer 
with resistance to gemcitabine-based chemotherapy.
Epelbaum et al[49] reported the results from another 
clinical trial testing the efficacy and feasibility of  cur-
cumin in combination with gemcitabine monotherapy in 
chemo-naive patients with advanced pancreatic cancer. 
Seventeen patients were enrolled in the study, and they 
received the standard dose and schedule of  gemcitabine 
in combination with an 8-g daily oral dose of  curcumin. 
In contrast to the previous 2 studies that showed low tox-
icity for 8-g daily oral doses of  curcumin[47,48], this study 
reported that 5 patients (29%) discontinued the curcumin 
regimen after a period of  several days to 2 wk due to 
intractable abdominal fullness and/or pain. Indeed, the 
dose of  curcumin was eventually reduced to 4 g/d due 
abdominal complaints in 2 other patients. The research-
ers discussed the possibility that increased gastrointestinal 
toxicity could be caused by the combination of  curcumin 
and gemcitabine, and they concluded that 8 g oral cur-
cumin is not a viable treatment dose when combined with 
gemcitabine in patients with pancreatic cancer. One pos-
sible explanation for the discrepancy between our results 
and those of  Epelbaum et al[49] is that the baseline clinical 
condition of  the patients was poorer in the Epelbaum et 
al[49] study than in ours, and therefore, the abdominal full-
ness or pain experienced by these patients may have been 
primarily attributable to cancer-related symptoms.
Table 2 summarizes the published clinical trials that 
have tested the effects of  curcumin in patients with pan-
creatic cancer.
APPLICATION OF A HIGHLY 
BIOAVAILABLE FORM OF CURCUMIN 
(THERACURMIN®) IN CLINICAL TRIALS
Several investigators, including ourselves, have tested 
plasma curcumin levels in clinical trials, and most stud-
ies have reported that plasma curcumin levels remained 
at low (ng/mL) levels, despite multi-gram doses of  cur-
cumin[42,45,46,48]. As described in the previous section, the 
intake of  oral doses of  curcumin greater than 8 g did not 
lead to further increases in plasma curcumin levels in hu-
man subjects[42-44]. Therefore, the poor bioavailability of  
curcumin has been the primary challenge to its clinical 
application. As a result, many efforts have been made to 
improve the bioavailability of  this agent using a variety 
of  approaches, including innovative drug delivery sys-
tems (nanoparticles, liposomes and phospholipids)[50-65] 
and the development of  new curcumin analogs[66,67]. For 
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Table 1  A summary of representative preclinical studies on 
the anticancer effects of curcumin against pancreatic cancer
Reported molecular targets Curcumin dose required for the reported 
effects
 in vitro  (μmol/L) in vivo
NF-kB↓ (Ref. 14) ≥ 5.4 NA





NF-kB↓, Sp-1, Sp-3, Sp4↓ ≥ 25 100 mg/kg per day, 
intraperitoneal injectioncyclin-D1↓, survivin↓
VEGF↓ (Ref. 27)
NF-kB↓, PGE2↓ ≥ 4 NA
VEGF↓, miR-21↓
miR-200↑ (Ref. 28)
cIAP1: Cellular inhibitor of apoptosis portein-1; MMP: Matrix metallopro-
teinase; COX2: Cyclooxygenase-2; VEGF: Vascular endothelial growth fac-
tor; PGE2: Prostaglandin E2; NA: Not available. 
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CURMIN® can lead to higher plasma curcumin levels 
than those achieved with conventional curcumin (Table 
3). Therefore, we considered this new form of  curcumin 
to be a promising tool for testing the potential anticancer 
effects of  curcumin in clinical trials, and we conducted a 
phase Ⅰ study testing the safety of  THERACURMIN® in 
patients with pancreatic cancer[69].
A total of  16 patients (14 patients with pancreatic 
cancer and 2 patients with biliary tract cancer) who failed 
standard gemcitabine-based chemotherapy were enrolled 
in the study. Based on our previous pharmacokinetic 
study, we chose to use THERACURMIN® containing 
200 mg curcumin (Level 1) as the starting dose. THERA-
CURMIN® was administered orally every day in combi-
nation with standard gemcitabine-based chemotherapy. 
Ten patients were assigned to the Level 1 group and 
six to the Level 2 group (THERACURMIN® contain-
ing 400 mg curcumin). Peak plasma curcumin levels 
(median) following THERACURMIN® administration 
were 324 ng/mL (range = 47-1029 ng/mL) for Level 1 
and 440 ng/mL (range = 179-1380 ng/mL) for Level 2. 
Importantly, these values were significantly higher than 
the median value (85 ng/mL) observed in our previous 
study using 8-g doses of  conventional curcumin (Figure 
2). With respect to safety, two patients reported increased 
abdominal pain following THERACURMIN® adminis-
tration. Computed tomography scans performed prior 
to THERACURMIN® administration in these patients 
revealed dilated colons, which could have been due to in-
example, a nanoparticle-based drug delivery system has 
been shown to improve the water solubility of  hydro-
phobic agents such as curcumin, and several different 
types of  nanoparticle-based curcumin have been pub-
lished[52,56-59,61,62,64,65].
Of  these new varieties of  nanoparticle-based curcum-
in, we chose THERACURMIN® for further study, as it 
showed a greater than 30-fold increase in bioavailability 
compared with conventional curcumin in rat models[64]. 
THERACURMIN® was prepared as follows[64,68]. First, 
gum ghatti - which primarily consists of  polysaccharides 
obtained from ghatti tree exudates - was dissolved in 
water to make a gum ghatti solution. Curcumin powder 
was mixed into this solution, and water and glycerin 
were added to adjust the final weight. This mixture was 
ground using a wet grinding mill (DYNO-MILL®KDL, 
Willy A Bachofen AG) and then dispersed with a high-
pressure homogenizer (Homogenizer 15MR-8TA, APV 
Gaulin). Stable THERACURMIN® is obtained from this 
procedure.
To verify the improved bioavailability of  THERA-
CURMIN® in human subjects, we conducted a dose-es-
calation and pharmacokinetic study[68]. Six healthy human 
volunteers were recruited and given THERACURMIN® 
via a single oral dose of  150 mg. Following an interval of  
2 wk, the same subjects were then given THERACUR-
MIN® via a single oral dose of  210 mg. The Cmax values 
for THERACURMIN® at the 150 and 210 mg doses were 
189 ± 48 and 275 ± 67 ng/mL (mean ± SEM), respec-
tively. No toxicity associated with THERACURMIN® 
intake was observed in this study.
These results indicate that the ingestion of  THERA-
Table 2  A summary of published clinical trials testing curcumin in patients with pancreatic cancer
Dhillon et al [47] Kanai et al [48] Epelbaum et al [49] Kanai et al [69]
Sample size 25 21 17 14
Study design Phase Ⅱ Phase Ⅰ/Ⅱ Phase Ⅱ Phase Ⅰ
Study period 20081 2008-2009 2004-2006 2011-2012
Dose of curcumin 8 g/d 8 g/d 8 g/d 200 mg/d2 (n = 9) 400 mg/d2 (n = 5)
Prior history of chemotherapy Yes (n = 22) Yes (n = 21) None yes (n = 14)
Concomitant use of anticancer drug No Yes Yes Yes
Major toxicity associated with curcumin None None Abdominal discomfort (n = 5) Abdominal pain (n = 2)
Median survival time (mo) NA 5.4 5 4.4
1Publication year; 2THERACURMIN® was used in this study. NA: Not available. 
Table 3  A comparison of representative studies reporting 









Sample size 3 (1)1 3 3 6
Dose of curcumin 
(g/d)




57 4 ± 0.2 < 1 275 ± 67 






















Figure 2  Plasma curcumin levels following administration of conventional 
curcumin and THERACURUMIN®. Each point corresponds to an individual 
patient. Bars denote the median value. Adapted from Kanai et al[69]. 
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testinal obstructions caused by peritonitis carcinomatosa. 
As described in the previous section, Epelbaum et al[49] 
reported abdominal fullness or pain following curcumin 
administration in patients with pancreatic cancer. We 
speculate that curcumin may irritate the intestine, poten-
tially increasing abdominal pain in patients with intestinal 
obstructions due to peritonitis carcinomatosa or other 
complications. In future clinical trials, we advise caution 
when administering curcumin to these types of  patients.
Other observed toxicities were comparable to those 
for gemcitabine-based chemotherapy alone, and repeti-
tive exposure to high concentrations of  curcumin did 
not cause any unexpected serious adverse events, nor 
did they increase the incidence of  adverse events in pa-
tients with pancreatic cancer receiving gemcitabine-based 
chemotherapy. In fact, three patients safely continued 
THERACURMIN® treatment for > 9 mo. With respect 
to efficacy, no responses were observed in this study 
based on RECIST; however, the MST was 4.4 mo (95% 
confidence interval: 1.8-7.0 mo) for the 14 patients with 
pancreatic cancer, and three patients (21%) survived for 
> 12 mo following initiation of  THERACURMIN®.
Interestingly, fatigue- and functioning-associated qual-
ity of  life (QOL) scores scaled by EORTC QLQ-C30 
significantly improved following THERACURMIN® ad-
ministration. In five patients, the fatigue score improved 
by > 20, which was interpreted as a significant and clini-
cally relevant change[70]. Preclinical and clinical studies 
demonstrating the benefits of  curcumin on heart disease, 
depression, and fatigue, also support these findings[71-73]. 
As improved QOL has been demonstrated to contribute 
to better outcomes in cancer patients[74], it is tempting to 
speculate that THERACURMIN® may prolong the over-
all survival of  patients with pancreatic cancer through 
QOL improvements. A randomized placebo-controlled 
clinical trial is now underway to verify this hypothesis 
(UMIN000010326).
CONCLUSION
A growing body of  evidence supports the idea that cur-
cumin is a promising anticancer drug. In preclinical mod-
els, curcumin has been shown to have anticancer effects, 
both alone and in combination with other anticancer 
drugs, through the modulation of  a variety of  molecular 
targets. However, the poor bioavailability of  curcumin 
has been the major challenge to its clinical application. 
This problem has now been solved by the development 
of  highly bioavailable forms of  curcumin (THERA-
CURMIN®), which can induce higher plasma curcumin 
levels without increased toxicity. Further clinical trials will 
be necessary to test the therapeutic applications of  this 
promising agent in patients with pancreatic cancer.
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